Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

Updated [212Pb]VMT-α-NET cohort data will be shared in a poster session at a major oncology drug development meeting in November 2026.

Rhea-AI Summary

Perspective Therapeutics (CATX) reports that updated data from its [212Pb]VMT-α-NET program have been accepted for presentation at the 38th EORTC-NCI-AACR Symposium 2026 in Barcelona.

The poster, led by Vikas Prasad of Washington University School of Medicine, will show cohort-level safety and efficacy results for [212Pb]VMT-α-NET in advanced SSTR2-positive neuroendocrine tumors (NETs), covering Cohorts 1–3, as Abstract 334 in the “New drugs” poster session on November 20, 2026.

[212Pb]VMT-α-NET is being evaluated in a multi-center, open-label, dose-escalation and dose-expansion trial (NCT05636618) in unresectable or metastatic SSTR2-positive tumors without prior radiopharmaceutical therapy, with additional data submissions planned for 2026 and 2027.

News Explained

The accepted poster is not yet a complete results release: data cut on April 17, 2026 included efficacy results for half of Cohort 2 and both Cohort 1 patients, while initial efficacy results for the remaining Cohort 2 patients and Cohorts 3–4 are still pending. Further abstract details are planned for November 4, 2026.

Key Figures

Presentation date: November 20, 2026 Abstract release date: November 4, 2026

Presentation date

November 20, 2026

Cohort-level safety and efficacy results for [212Pb]VMT-α-NET

Abstract release date

November 4, 2026

Further abstract details

Key Terms

radiopharmaceutical, sstr2, dose-escalation, theranostic

4 terms

radiopharmaceutical medical

"a radiopharmaceutical development company pioneering advanced treatments"

A radiopharmaceutical is a special type of medicine that contains a small amount of radioactive material, used primarily for medical imaging or treatment. It can be thought of as a tiny, targeted signal that helps doctors see inside the body or deliver therapy directly to affected areas. For investors, understanding radiopharmaceuticals is important because they represent a growing field within healthcare, driven by advancements in diagnostics and personalized treatments.

sstr2 medical

"somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors"

sstr2 is a protein on the surface of some cells that acts like a lock for the hormone somatostatin and similar drugs; many neuroendocrine tumors have lots of these locks. For investors, sstr2 matters because tests and medicines that find or fit this lock — such as targeted imaging agents and therapies — can enable diagnosis, guide treatment decisions, and create commercial opportunities if they gain regulatory approval and clinical adoption.

dose-escalation medical

"a multi-center, open-label, dose-escalation and dose-expansion study"

Dose-escalation is the part of an early-stage clinical trial where researchers gradually increase a drug’s dose in small groups of participants to find the safest and most effective amount. Think of it like turning up the volume slowly to find the sweet spot: investors watch these results closely because they reveal safety risks, potential effectiveness, and how quickly a drug can move to later trials or approval, all of which affect the development timeline and commercial prospects.

theranostic medical

"This "theranostic" approach enables visualization of the specific tumor"

A theranostic is a single medical approach or agent that combines diagnosis and treatment—using a test or imaging step to find patients likely to benefit, then delivering a targeted therapy tied to that same marker. For investors, theranostics can speed development, lower the chance of failed trials and concentrate sales on the right patients, like a smart key that both locates the correct lock and opens it, potentially improving clinical and commercial success.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [²¹²Pb]VMT-α-NET program have been accepted for presentation as detailed below at the 38th EORTC-NCI-AACR (ENA) Symposium 2026 on Molecular Targets and Cancer Therapeutics taking place November 18 to 20, 2026 in Barcelona, Spain. The conference plans to release further details for abstracts on November 4, 2026.

Presenter	Abstract Title	Presentation Details
Vikas Prasad, Washington University School of Medicine	Cohort level safety and efficacy results for [212Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1–3	Abstract Number: 334 Session Type: Poster session Session Title: New drugs Session Date: November 20, 2026 Session Time: 9:00am – 3:00pm CET / 3:00am – 9:00 am EST

About [²¹²Pb]VMT-α-NET

Perspective designed [²¹²Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [²¹²Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT).

Interim clinical data from the study, with a data cut-off date of April 17, 2026, were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026. These data included efficacy results for half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and patients in Cohorts 3 and 4 are pending. The Company plans to submit additional data for presentation at future medical conferences in 2026 and 2027.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary ²²⁴Ra/²¹²Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s beliefs that its product candidates address certain unmet medical needs; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com

FAQ

When and in which session will the [212Pb]VMT-α-NET poster be presented?

The [212Pb]VMT-α-NET data will be presented on November 20, 2026, during the “New drugs” poster session at the 38th EORTC-NCI-AACR (ENA) Symposium 2026, scheduled from 9:00am to 3:00pm CET (3:00am to 9:00am EST), as Abstract Number 334.

What is [212Pb]VMT-α-NET and which patients are enrolled in its current study?

[212Pb]VMT-α-NET is designed to target somatostatin receptor subtype 2 (SSTR2) and deliver the alpha-emitting isotope lead-212 (212Pb) to SSTR2-expressing tumors. It is being tested in a multi-center, open-label, dose-escalation and dose-expansion study (NCT05636618) in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies.

What interim data have already been shared from the [212Pb]VMT-α-NET trial?

Interim clinical data with a cut-off of April 17, 2026 were presented at the 2026 ASCO Annual Meeting, including efficacy results for half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and for patients in Cohorts 3 and 4 are still pending.

What other clinical-stage programs is Perspective Therapeutics advancing?

The company is advancing clinical-stage programs including bamzireotide navoxetan (VMT-α-NET) for neuroendocrine tumors, lapemelanotide zapixetar (VMT01) for melanoma, and PSV359 for solid tumors, using its 212Pb-based theranostic platform.